Home > Neurology > EAN 2019 > Multiple Sclerosis > Treating MS from disease onset

Treating MS from disease onset

Presented By
Dr Kjell-Morten Myhr, Haukeland University Hospital, Norway
Conference
EAN 2019
Recent EAN/ECTRIMS guidelines highlight the need for early introduction of disease-modifying treatment (DMT). However, a study presented at the EAN 2019 illustrated that this is still far from reality in clinical practice. The results showed that time to first DMT varies strongly across countries [1]. Another study illustrated the importance of timely management by showing that MS patients have an increased risk of death, with pneumonia being the most common cause [2]. The two studies were pointed out in a highlights session by Dr Kjell-Morten Myhr (Haukeland University Hospital, Norway). Stahmann et al. investigated the time to first DMT after diagnosis in 3 large MS registry populations: NARCOMS, United Kingdom (UKMSR), and Germany (GMSR) [1]. Inclusion criteria were a relapsing disease course, diagnosis in 2014 or later, and provided data on DMT and disability status. Criteria were met by 2,506 participants (325 in NARCOMS, 453 in UKMSR, and 1,728 in GM...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on